Astellas Pharma Inc. revised consolidated earnings guidance for the full year ending March 2022. For the year, the company expects revenue of JPY 1,323,000 million compared to previous forecast of JPY 1,323,000 million; operating profit of JPY 218,000 million compared to previous forecast of JPY 227,000 million; profit for the year of JPY 174,000 million compared to previous forecast of JPY 183,000 million; and basic earnings per share of JPY 93.90 compared to previous forecast of JPY 98.76.